Hanwha Offers Up to $1.2 Billion for Austal US Business 
Treasury Wine Estates Shares Jump as U.S. Overhaul Lifts FY2026 Outlook 
Alibaba Plans Revenue-Sharing Model for Qwen3.8-Max AI Commercial Users 
Hims & Hers Shares Fall as GLP-1 Costs Widen Q2 Loss 
Daimler Truck Q2 Profit Falls 18%, 2026 Outlook Raised 
ADNOC Gas Targets Up to $4B Profit in 2026 
Natura Q2 Profit Plunges 92% as Financial Expenses Weigh on Earnings 
Goldman Sachs Sees US Stock Buybacks Outpacing Equity Issuance as AI Funding Rises 
AMP Shares Surge 13% After Strong Profit and A$150 Million Buyback 
Sony, TSMC Eye $6.3 Billion Japan Chip Venture for Next-Gen Image Sensors 
Nintendo Shares Jump as Switch 2 Sales Boost Earnings 
Shein Scales Back Vietnam Operations as US Trade Rules Shift 
Nvidia Seen Beating Q2 Targets as Vera Rubin Cycle Begins 
Cloudflare Stock Jumps 15% as Earnings Beat Estimates, 2026 Outlook Raised 
Apple Tests China’s CXMT Memory Chips for iPhones and MacBooks Amid AI Supply Crunch 
UOB Q2 Net Profit Rises 10% as Wealth Management Growth Boosts Earnings 
Berkshire Hathaway Cash Falls as Abel Boosts Stock Buybacks 
Drugmakers including Pfizer Inc, Sanofi SA, and GlaxoSmithKline Plc are raising prices on over 300 drugs in the US on Jan. 1 due to reduced demand for some drugs triggered by the pandemic.
As lesser doctor visits on account of the pandemic resulted in less demand for some drugs, the drugmakers are also fighting new price-cutting rules from the Trump administration, which would reduce their profitability.
Pfizer and Sanofi kept nearly all of their increases at five percent or less.
GSK raised prices on Shingrix, a vaccine for shingles, by 7 percent, and Pediarix, a vaccine for diphtheria, tetanus, and pertussis, by 8.6 percent.
Teva Pharmaceuticals Inc hiked prices on 15 drugs, including Austedo, which treats rare neurological disorders, asthma steroid Qvar, muscle relaxant Amrix, and narcolepsy treatment Nuvigil, as much as 9.4 percent.
More price hikes are set for early January.
Pfizer plans to increase prices on over 60 drugs by as much as 5 percent, including rheumatoid arthritis treatment Xeljanz and cancer drugs Inlyte and Ibrance.
According to Pfizer spokeswoman Amy Rose, the increase would support investments that allow them to discover new medicines and deliver those breakthroughs.
Sanofi will announce more price increases later in January, according to spokesperson Ashleigh Koss.
Slashing prescription drug prices was a core pledge of a focus of US President Donald Trump's 2016 campaign.
President-elect Joe Biden has also vowed to cut drug prices..
